Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice
International Journal of Molecular Sciences · 31.03.2023 · 24 (7) · 6554
DOI: 10.3390/ijms24076554 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.03.2023. Verfasst von Yanghuan Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Genetics of Aging and Tumor, Medical School, Kunming University of Science and Technology, Kunming 650500, China. Hauptthemen laut MEDLINE: Cellular Senescence, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China to J.L, The Yunnan Fundamental Research Project to S.J., National Natural Science Foundation of China.
Abstract (Originalsprache)
Accumulating evidence indicates that the increased burden of senescent cells (SCs) in aged organisms plays an important role in many age-associated diseases. The pharmacological elimination of SCs with “senolytics” has been emerging as a new therapy for age-related diseases and extending the healthy lifespan. In the present study, we identified that cycloastragenol (CAG), a secondary metabolite isolated from Astragalus membrananceus, delays age-related symptoms in mice through its senolytic activity against SCs. By screening a series of compounds, we found that CAG selectively kills SCs by inducing SCs apoptosis and that this process is associated with the inhibition of Bcl-2 antiapoptotic family proteins and the PI3K/AKT/mTOR pathway. In addition, CAG treatment also suppressed the development of the senescence-associated secretory phenotype (SASP) in SCs, thereby inhibiting cell migration mediated by the SASP. Furthermore, the administration of CAG for 2 weeks to mice with irradiation-induced aging alleviated the burden of SCs and improved the animals’ age-related physical dysfunction. Overall, our studies demonstrate that CAG is a novel senolytic agent with in vivo activity that has the potential to be used in the treatment of age-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Genetics of Aging and Tumor, Medical School, Kunming University of Science and Technology, Kunming 650500, China.
ORCID-Profile: Runzi Zheng, Shuting Jia
Förderung
- The National Natural Science Foundation of China to J.L
- The Yunnan Fundamental Research Project to S.J.
- National Natural Science Foundation of China
- Yunnan Fundamental Research Project
Zitieren
APA
Zhang, Y., Gao, D., Yuan, Y., Zheng, R., Sun, M., Jia, S., & Liu, J. (2023). Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice. International Journal of Molecular Sciences, 24(7), 6554. https://doi.org/10.3390/ijms24076554
Vancouver
Zhang Y, Gao D, Yuan Y, Zheng R, Sun M, Jia S, et al. Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice. International Journal of Molecular Sciences. 2023;24(7):6554. doi:10.3390/ijms24076554
BibTeX
@article{Zhang2023,
author = {Zhang, Yanghuan and Gao, Dongxiao and Yuan, Yang and Zheng, Runzi and Sun, Manting and Jia, Shuting and Liu, Jing},
title = {Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {7},
pages = {6554},
doi = {10.3390/ijms24076554}
}
EUVIMED